Publication for CCNA2 and PRC1

Species	Symbol	Function*	Entrez Gene ID*	Other ID	Gene coexpression	CoexViewer
hsa	CCNA2	cyclin A2	890			[link]
hsa	PRC1	protein regulator of cytokinesis 1	9055

Pubmed ID	Priority	Text
31572440	0.97	PRC1, CDKN3, CDK1 and CCNA2 are significant weighted prognostic factors, and that an integrated gene panel may serve as an independent penal in ACC samples.
	0.96	PRC1, CDKN3, CDK1 and CCNA2.
	0.95	PRC1, CDKN3, CDK1 and CCNA2 is significantly associated with worse OS and DFS, indicating that these genes may play important roles in the aggressive malignant phenotypes of ACC.
	0.94	PRC1, CDKN3, CDK1 and CCNA2, respectively.
	0.93	PRC1, CDKN3, CDK1 and CCNA2.
	0.92	PRC1, CDKN3, CDK1 and CCNA2 are of prognostic value, and may assist in better understanding the underlying carcinogenesis or progression of ACC.
	0.91	PRC1, CDKN3, CDK1, CCNA2) still consist of this new module penal ( Supplementary Figure 4C ), indicating a good stability of our molecular model.
	0.75	PRC1, CDKN3, CDK1 and CCNA2 were highly expressed in ACC samples ( Figure 3F ).
	0.73	PRC1, CDKN3, CDK1 and CCNA2 are of high prognostic value, and may help us understand better the underlying carcinogenesis or progression of ACC.
	0.56	PRC1, CDKN3, CDK1 and CCNA2.
	0.54	CCNA2, ZWINT, BIRC5, KIAA0101, TOP2A, BUB1B, CCNB1, AURKA, SMC2, ATAD2, PRC1, TPX2, CDK1, RACGAP1, TYMS, ANLN, PRIM1, NUSAP1, CENPF, SPAG5, SMC4, EZH2, FANCI.
31402959	0.97	CCNA2, cyclin-A2; TOP2A, DNA topoisomerase 2-alpha; AURKA, Aurora kinase A; BIRC5, baculoviral IAP repeat-containing protein 5; CENPN, centromere protein N; RACGAP1, Rac GTPase-activating protein 1; PRC1, protein regulator of cytokinesis 1; CDKN3, cyclin-dependent kinase inhibitor 3.
	0.94	cyclin-A2 (CCNA2), DNA topoisomerase 2-alpha (TOP2A), Aurora kinase A (AURKA), baculoviral IAP repeat-containing protein 5 (BIRC5), centromere protein N (CENPN), Rac GTPase-activating protein 1 (RACGAP1), protein regulator of cytokinesis 1 (PRC1) and cyclin-dependent kinase inhibitor 3 (CDKN3) (Fig. 11B).
	0.94	CCNA2, TOP2A, AURKA, BIRC5, CENPN, RACGAP1, PRC1 and CDKN3 were 0.968, 0.962, 0.965, 0.985, 0.947, 0.959, 0.830, 0.871, 0.971 and 0.936, respectively (Fig. 12).
	0.69	CCNA2; (D) TOP2A; (E) AURKA; (F) BIRC5; (G) CENPN; (H) RACGAP1; (I) PRC1; and (J) CDKN3.
	0.60	CCNA2, cyclin-A2; TOP2A, DNA topoisomerase 2-alpha; AURKA, Aurora kinase A; BIRC5, baculoviral IAP repeat-containing protein 5; RACGAP1, Rac GTPase-activating protein 1; PRC1, protein regulator of cytokinesis 1.
23874428	0.97	CCNA2 (Cyclin A2), CCNB2 (Cyclin B2), CDK1, CDK5, CDC27, CDCA5, CDCA8, ASPM, BUB1, KIF15, KIF2C, NEK2, NUSAP1, PRC1, SMC4, SYCE2, TFDP1, CDC42 and ARHGEF9 are present that play a crucial role in cell cycle progression.
	0.90	CCNA2 (Cyclin A2), CCNB2 (Cyclin B2), CDK1, CDK5, CDC27, CDCA5, CDCA8, ASPM, BUB1, KIF15, KIF2C, NEK2, NUSAP1, PRC1, SMC4, SYCE2, TFDP1, CDC42 and ARHGEF9 (CDC42 regulator) that show over-expression in lung adenocarcinoma.
32046048	0.97	PRC1, ASPM, NUSAP1, UBE2C, CDC20, CCNA2, and KIF20A (Figure 3).
	0.97	PRC1, ASPM, NUSAP1, UBE2C, CDC20, CCNA2, and KIF20A.
16729057	0.97	CCNA2, BIRC5, CDC2, CDC25C, PRC1, POLD1, PLK, and others were previously shown to be downregulated by p53, validating our analysis and enabling us to propose numerous novel p53 transrepression targets.
30906836	0.97	PRC1, CDCA8, CCNA2, CDC20, BIRC5, BUB1B, MAD2L1, ZWILCH, CKAP5, KIF18A, KIF2C, CENPE, CENPF, CENPK, KIF20A, CCNB1 are the genes found in the top cluster with high interaction.
31086582	0.97	PRC1, AURKA, stratifin (SFN), CCNA2, CDC25A and KIF20A were significantly associated with protein kinase binding (P=7.10x10-4).
17594496	0.96	CCNA2, CCNB1, CDC2, CDC2L2, CCNB2, CDKN2C, CDKN3, CKS1B, CKS2, KIF11, KIF23, KPNA2, PCNA, MAD2L1, PRC1, PTTG1, RAD21, SMC4L1, UBE2C and others).
24400072	0.96	PRC1, KIFC1, PTTG1, AURKB, KIF23, KIF11, KIF20B, CENPE, ASPM, TTK, MAD2L1, NUF2, CDC20, CCNA2 and CCNB2, were highly expressed in CC1 MSCs compared to CC2 MSCs (Fig. 3C, Table 3).
25573623	0.96	protein regulator of cytokinesis 1 (PRC1), topoisomerase II alpha (TOP2A), cyclin B1 (CCNB1), cyclin-dependent kinases regulatory subunit 2 (CKS2) and cyclin A2 (CCNA2), while EGFR was in cluster4.
26743006	0.96	PRC1, SKA3 and UBE2C) and four of our previously identified CREB1/FoxA1 target genes (CCNA2, CCNE2, E2F1 and CDK1) for further analysis (Supplementary Figure S8B).
31043166	0.96	CCNA2, CCNB2, PRC1, and RRM2.
29871693	0.95	PRC1 (AUC = 0.862), CCNB2 (AUC = 0.847), BIRC5 (AUC = 0.838), PTTG1 (AUC = 0.831), CCNA2 (AUC = 0.827), E2F1 (AUC = 0.826), KIF11 (AUC = 0.826), CDC25A (AUC = 0.823), UBE2C (AUC = 0.82), and CDK1 (AUC = 0.817) as the top 10 genes obtaining the best classification performance.
	0.90	PRC1 (AUC = 0.761), CCNA2 (AUC = 0.757), ACTG2 (AUC = 0.756), CCNB1 (AUC = 0.755), RND3 (AUC = 0.752), KIF23 (AUC = 0.751), and CLDN8 (AUC = 0.749) as the top 10 genes.
26992853	0.95	CCNA2), clustering centrosomes (PRC1), microtubule spindle (KIF11, NUSAP1, NUMA1) etc.
28825947	0.95	PRC1, CCNB2, CDK1, KIF11, CCNB1), DNA damage-induced 14-3-3 Sigma Signaling (CCNE2, CCNB2, CDK1, CCNB1) and G2M DNA damage checkpoint regulation (TOP2A, CCNB2, CDK1, CHEK1, CCNB1), Cyclins and cell cycle regulation (Cyclins A2, B1, B2, E2 and CDK1), Eumelanin Biosynthesis (TYR, DCT) and Melanocyte Development and Pigmentation Signaling (TYRP1, TYR, DCT, SOX10), the role of CHK Proteins in cell Cycle Checkpoint Control (CDK1, CHEK1, RCF3), the antiproliferative role of TOB in T Cell signaling (CCNA2, CCNE2) and the p53 signaling (BIRC5, CHEK1, SERPINE2).
29572470	0.91	CCNA2, CDC6, CENPN, CLIC2, DLGAP5, INSIG1, KIAA0101, NR4A2, NUF2, NUSAP1, PRC1, TPX2, and TXN, with fold change increases in the range of 2.12-7.73 and p-value < 0.02 (Wilcoxon rank-sum test).
24067424	0.88	Ccna2, Prc1, Ccnb1, Bub1b, Gins1, Ns5atp9, Melk, Tyms, Aspm, Aurka, Ccne2, Bard1, E2f8, Dtl, Cep55, Kif20a, and Espl1.
23170111	0.77	PRC1, MCM4, CDC20, CDC45L, CCNA1, CCNB2, CCNA2, TOP2A and CDCA7), angiogenesis (5% of total gene expression changes: PGF, ANGPT2, ANGPTL4 and RGS4) and ubiquitin modifications (3% of total gene expression changes: UBE2T, UBE2C and UHRF1).